Equasens (EQS) AI Stock Analysis

• Market Cap: €668.41M
• Dividend Yield: 2.81%
• Average Volume (3M): 9.00K
• Price to Earnings (P/E): 18.5
• Beta (1Y): 0.64
• Revenue Growth: 4.47%
• EPS Growth: -14.37%
• Country: FR
• Employees: 1,271
• Sector: Services
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.14
• Shares Outstanding: 15,174,125
• 10 Day Avg. Volume: 9,309
• 30 Day Avg. Volume: 9,003
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €50.00
• Price Target Upside: 12.36% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: €50.00 ▲(12.36% Upside)

Equasens' strong financial performance is the most significant factor, showcasing robust revenue growth and solid profitability. However, the technical analysis indicates bearish momentum, which weighs down the overall score. The valuation is fair, providing a balance between growth and income potential. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Negative Factors

Equasens Business Overview & Revenue Model

Company Description

Equasens (EQS) is a leading player in the healthcare technology sector, specializing in the development and integration of telemedicine solutions, digital health platforms, and connected medical devices. The company focuses on enhancing patient care and streamlining healthcare processes through innovative technology, catering to both healthcare professionals and patients. Its core products include remote monitoring systems, health management applications, and data analytics services designed to improve health outcomes and operational efficiencies in various healthcare settings.

How the Company Makes Money

Equasens generates revenue through multiple streams, primarily by offering subscription-based models for its telemedicine and digital health platforms. Revenue is also derived from the sale of connected medical devices that enable remote patient monitoring and data collection. Additionally, the company partners with healthcare institutions and insurance providers to implement its technology solutions, often leading to contractual agreements that secure ongoing service fees. Significant partnerships with technology firms and healthcare organizations enhance its market reach and contribute to its revenue through collaborative projects and shared technology initiatives.

Equasens Financial Statement Overview

Summary

Equasens presents a strong financial profile with consistent revenue growth and solid profitability margins. The balance sheet reflects stability with a healthy equity position, while cash flow statements confirm strong cash generation. Despite slight challenges in revenue growth and rising liabilities, the company's financial health remains robust, supported by efficient operations and financial management.

Income Statement

Equasens has demonstrated consistent revenue growth over the years, with a compound annual growth rate in revenue evident from 2019 to 2023. The gross profit margin and EBIT margin have been healthy, indicating effective cost management and operational efficiency. However, a slight decrease in revenue from 2023 to 2024 suggests a potential challenge in sustaining growth, although margins remain strong.

Balance Sheet

Equasens exhibits financial stability with a strong equity ratio, indicating a solid financial foundation. The debt-to-equity ratio remains manageable, showcasing prudent leverage management. The return on equity is commendable, although a slight increase in liabilities in recent years suggests a need to monitor debt levels closely.

Cash Flow

The company maintains robust cash flow generation capabilities, with positive free cash flow and a consistent operating cash flow to net income ratio. Free cash flow growth has been notable, supporting ongoing investments and financial flexibility. The cash flow management reflects strong operational health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	216.80M	219.79M	214.07M	193.07M	171.75M
Gross Profit	47.13M	69.88M	145.52M	133.82M	119.31M
EBITDA	45.10M	71.30M	67.36M	63.77M	55.82M
Net Income	36.20M	47.05M	46.38M	39.12M	30.71M
Balance Sheet
Total Assets	398.01M	394.05M	350.81M	329.95M	295.78M
Cash, Cash Equivalents and Short-Term Investments	40.16M	54.69M	68.01M	64.79M	63.28M
Total Debt	48.45M	69.27M	18.08M	76.46M	64.13M
Total Liabilities	157.32M	166.42M	154.01M	164.72M	146.82M
Stockholders Equity	231.51M	219.28M	189.78M	159.00M	143.26M
Cash Flow
Free Cash Flow	35.91M	43.17M	46.75M	37.09M	27.53M
Operating Cash Flow	47.55M	61.59M	56.98M	47.52M	47.21M
Investing Cash Flow	-13.90M	-50.53M	-18.34M	-36.19M	-39.14M
Financing Cash Flow	-36.20M	-16.09M	-38.27M	-9.80M	2.82M

Equasens Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 44.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Negative. The current price of 44.5 is below the 20-day moving average (MA) of 44.81, below the 50-day MA of 47.60, and above the 200-day MA of 42.58, indicating a neutral trend. The MACD of -0.55 indicates Negative momentum. The RSI at 42.17 is Neutral, neither overbought nor oversold. The STOCH value of 57.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EQS.

Equasens Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQS	67 Neutral	€668.41M	18.49	16.07%	2.81%	4.47%	-14.37%
BLC	66 Neutral	€175.15M	103.90	―	―	3.24%	-75.05%
LNA	65 Neutral	€259.46M	12.28	6.95%	5.22%	13.31%	-13.07%
ALERS	58 Neutral	€253.14M	108.07	2.24%	―	12.75%	-65.94%
ALCGM	54 Neutral	€145.37M	-10.27	-5.56%	―	3.79%	-797.10%
GDS	48 Neutral	€1.10B	-20.37	-4.72%	―	4.70%	-0.33%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%